Los Angeles Times
Sunday, February 4, 2001
FDA Fails to Give Olestra Fair Weight
By HENRY MILLER
STANFORD--The sad truth is that we are
a bunch of fatsos, and getting fatter. Sixty-one percent of American adults
are overweight, an all-time high, and more than a quarter are obese, or grossly
overweight, according to a 1999 survey just released by the national Centers
for Disease Control and Prevention.
But although we get fatter
and suffer from diabetes and high cholesterol in record numbers,
federal regulators are drastically limiting the availability
of an important tool for controlling calories.
Five years ago, the Food
and Drug Administration approved a potentially formidable weapon
in the war against dietary fat--a cooking oil called Olestra,
which adds no fat or calories to food. (It is simply a molecule
of table sugar linked to soybean or cottonseed oil that is too
large for the body to absorb or digest.)
In 1996, after analyzing
copious data, consulting outside experts and becoming convinced
of the product's safety during an eight-year review, the FDA
permitted the use of Olestra in chips, crackers and other "savory
snacks."
Since then, fat-free and
low-fat Olestra versions of five of the most popular chip brands
in the United States have been introduced by Frito-Lay, the world's
largest chip manufacturer, and by Proctor & Gamble Co., the
maker of Olestra and Pringles potato chips.
Olestra has been a real
success, with more than 3 billion servings sold in the United
States. If those consumers had chosen to eat regular, full-fat
chips instead of Olestra-cooked chips, they would have consumed
an additional 225 billion calories and 33,000 tons of fat.
Olestra is a potential
boon to public health in this country, where diets are dominated
by fat and three of the top four biggest health concerns--heart
disease, cancer and elevated blood cholesterol--are related to
fat consumption. Olestra can help lower the proportion of fat
and saturated fat in the diet, as well as to cut calories.
How widely might Olestra
be used? Four of the top five lunch and dinner entrees consumed
in U.S. homes could be made lower in fat with such a versatile
fat substitute: Pizza (No. 1) could be made with Olestra oil;
ham and turkey sandwiches (No. 2 and No. 5, respectively) could
contain Olestra mayonnaise; peanut butter, on a sandwich (No.
3), could be made with Olestra substituted for peanut oil; and
hot dogs (No. 4) could contain leaner meat, with Olestra added
for the mouth-satisfying "feel" of fat.
Although Olestra causes
mild gastrointestinal symptoms in a small number of consumers,
the frequency is no greater than with regular, full-fat chips.
A large clinical study by Johns Hopkins University, for example,
showed no statistically significant differences in reports of
digestive symptoms in 1,000 moviegoers who consumed either Olestra-cooked
potato chips or full-fat chips (without knowing which they were
eating). The peer-reviewed study was published in 1998 in the
Journal of the American Medical Assn.
The consumption of Olestra
chips has been shown, in these and other tests, to cause no more
severe or frequent problems than other common foods. For example,
milk and tea also bind vitamins and minerals. Moreover, studies
in progress at the Fred Hutchinson Cancer Research Center in
Seattle have found that the addition of vitamins to Olestra snacks
(which is done routinely) prevents any reduction in overall vitamin
availability.
Beyond Olestra's safety,
recent research reveals that eating snacks containing Olestra
correlates with various measures of improved health. A study
by researchers at Fred Hutchinson found that people who eat Olestra
snacks ate lower levels of both total dietary fat and saturated
fat. Moreover, they had lower levels of unfavorable LDL cholesterol.
The level of cholesterol reduction (8%) was similar to that of
a high-fiber diet. Studies also show an association between Olestra
consumption and a decreased percentage of energy from fat; in
other words, people are using Olestra as an effective way to
eat less fat.
Researchers at the University
of Nebraska Medical Center recently found that eating foods made
with Olestra can provide significant benefits to people with
early signs of heart disease. In addition, while similar results
may be achieved with less palatable fat-free meals, dietary professionals
recognize the importance of providing foods that people will
eat because they taste good.
The bad news is on the
political front. FDA regulators have been far too conservative
with this boon to public health. They granted limited approval,
permitting Olestra only for fried snacks, although the product
is uniquely versatile and can be used instead of margarine, lard,
butter and other oils in frying, baking and sauteing. The agency
has been unenthusiastic about additional uses, even though the
safety and usefulness of the product are unquestioned. Olestra
is also the most tested food substance in history, having undergone
far more animal studies and human clinical trials than most prescription
drugs. But the FDA continues to require labels on foods containing
Olestra, warning about possible gastrointestinal symptoms, despite
repeated demonstrations that such problems are no more frequent
than for full-fat snacks.
Such labels mislead consumers
and discourage wider use of Olestra products. In June 1998, an
FDA advisory committee criticized the warning label, and the
FDA promised to fix or eliminate it by the end of last year.
The agency, however, has not kept its word. If the FDA refuses
to be an advocate for wider use of Olestra, it should at least
"do no harm."
Why would federal health
regulators unnecessarily restrict such a desirable and popular
product? They seem to have responded to the near-hysterical opposition
of the Washington-based Center for Science in the Public Interest.
This is the same brown-rice and carrot-juice crowd who warned
us of the health horrors lurking in Mexican, Chinese and Greek
food, and in movie-theater popcorn--largely because of the fat
content. For more than a decade, the organization has forsworn
common sense and overwhelming scientific evidence in attacking
Olestra. Its executive director, Michael Jacobson, has called
Olestra a "public health time bomb." He has also said
that "the only kind of label notice that would be acceptable
to [his group for Olestra] would be . . . a skull and crossbones."
Widespread use of Olestra
could enable more people to adhere to the American Heart Assn.'s
recommendation to consume less than 30% of calories from fat.
In meeting the goal to improve public health, more Olestra in
our diets could be tantamount to the recognition that lowering
blood pressure reduces heart disease and risk of stroke. As a
solution to Americans' constantly expanding waistlines and fat
consumption, it is the closest thing to a free lunch.
The FDA's failure to promote--let
alone to permit--wider use of Olestra represents the most lamentable
kind of regulatory decision-making. The regulators are cavalier
toward public health, preemptive of consumers' freedom to choose
and punitive toward Proctor&Gamble, a company that spent
hundreds of millions of dollars in good faith to develop a safe
and effective product.